The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials

Amy Kang^*, Brendan Smyth, Brendon L. Neuen, Hiddo J.L. Heerspink, Gian Luca Di Tanna, Hong Zhang, Clare Arnott, Carinna Hockham, Rajiv Agarwal, George Bakris, David M. Charytan, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, David C. Wheeler, Kenneth W. Mahaffey, Vlado Perkovic, Meg J. Jardine